Histogen Inc. (HSTO)
$0.31
Rating:
Recommendation:
-
| Symbol | HSTO |
|---|---|
| Price | $0.31 |
| Beta | 1.154 |
| Volume Avg. | 0.27M |
| Market Cap | 1.324M |
| Shares () | - |
| 52 Week Range | 0.3-1.62 |
| 1y Target Est | - |
| DCF Unlevered | HSTO DCF -> | |
|---|---|---|
| DCF Levered | HSTO LDCF -> | |
| ROE | -122.56% | Strong Sell |
| ROA | -213.27% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | - | |
| P/E | -0.11 | Neutral |
| P/B | 0.24 | Neutral |
Latest HSTO news
About
Download (Excel)Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.